Top-Rated StocksTop-RatedNASDAQ:GH Guardant Health (GH) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free GH Stock Alerts $26.16 +0.64 (+2.51%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$25.60▼$26.8350-Day Range$16.07▼$26.2452-Week Range$15.81▼$41.06Volume3.40 million shsAverage Volume2.41 million shsMarket Capitalization$3.20 billionP/E RatioN/ADividend YieldN/APrice Target$36.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Guardant Health alerts: Email Address Guardant Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.85 Rating ScoreUpside/Downside39.9% Upside$36.60 Price TargetShort InterestBearish8.79% of Shares Sold ShortDividend StrengthN/ASustainability-0.51Upright™ Environmental ScoreNews Sentiment0.12Based on 26 Articles This WeekInsider TradingAcquiring Shares$38,972 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.36) to ($3.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.55 out of 5 starsMedical Sector89th out of 931 stocksMedical Laboratories Industry5th out of 19 stocks 4.4 Analyst's Opinion Consensus RatingGuardant Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageGuardant Health has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Guardant Health's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.79% of the outstanding shares of Guardant Health have been sold short.Short Interest Ratio / Days to CoverGuardant Health has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Guardant Health has recently increased by 5.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGuardant Health does not currently pay a dividend.Dividend GrowthGuardant Health does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGuardant Health has received a 71.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Genomics analysis tools" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Guardant Health is -0.51. Previous Next 2.8 News and Social Media Coverage News SentimentGuardant Health has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Guardant Health this week, compared to 4 articles on an average week.Search Interest31 people have searched for GH on MarketBeat in the last 30 days. This is an increase of 82% compared to the previous 30 days.MarketBeat Follows10 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Guardant Health insiders have bought 1,945.77% more of their company's stock than they have sold. Specifically, they have bought $38,972.00 in company stock and sold $1,905.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Guardant Health is held by insiders.Percentage Held by Institutions92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Guardant Health's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Guardant Health are expected to grow in the coming year, from ($3.36) to ($3.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Guardant Health is -6.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guardant Health is -6.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGuardant Health has a P/B Ratio of 19.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Guardant Health's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution About Guardant Health Stock (NASDAQ:GH)Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Read More GH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GH Stock News HeadlinesMay 26 at 3:56 AM | americanbankingnews.comGuardant Health (NASDAQ:GH) Earns Overweight Rating from StephensMay 25, 2024 | bizjournals.comPeninsula cancer test maker lands key nod from FDA panel, a step toward a big paydayMay 24, 2024 | markets.businessinsider.comEvaluating Guardant Health: Insights From 5 Financial AnalystsMay 24, 2024 | za.investing.comExact Sciences stock drops as Guardant Health test supported by FDA panelMay 24, 2024 | msn.comFDA Advisory Panel Supports Approval Of Guardant Health's Blood Test For Colorectal Cancer ScreeningMay 24, 2024 | msn.comGuardant jumps as trading resumes after FDA AdCom vote on cancer testMay 24, 2024 | finance.yahoo.comGuardant Health Jumps — As Exact Sciences Slumps — On A Key FDA Move For Blood TestsMay 24, 2024 | investors.comGuardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer TestMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Guardant Health Amid Positive FDA Outlook and Market OpportunityMay 23, 2024 | businesswire.comFDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening OptionMay 23, 2024 | reuters.comU.S. FDA advisers back approval for Guardant's blood-based cancer testMay 23, 2024 | finance.yahoo.comNatera to Present at the 2024 Leerink Partners Healthcare Crossroads ConferenceMay 23, 2024 | markets.businessinsider.comGuardant Health Trading Suspended On Nasdaq Pending ShieldTM's Premarket Approval MeetingMay 23, 2024 | msn.comGuardant shares on hold for trading ahead of AdCom meeting on cancer testMay 23, 2024 | businesswire.comGuardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer ScreeningMay 22, 2024 | businesswire.comGuardant Health to Participate in Upcoming Investor ConferencesMay 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: TELA Bio (TELA), Rezolute (RZLT)May 21, 2024 | reuters.comUS FDA staff says Guardant's cancer test may fail to detect some tumorsMay 21, 2024 | msn.comGuardant Health slips as FDA comments on cancer screening testMay 21, 2024 | businesswire.comTrinity Industries, Inc. Announces Offering of Additional 7.750% Senior Notes Due 2028May 21, 2024 | businesswire.comGuardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic IndicationsMay 17, 2024 | businesswire.comGuardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2024 | businesswire.comGuardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease WeekMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Guardant Health Amid Strong Q1 Performance and Positive Revenue OutlookMay 13, 2024 | benzinga.comMarket Whales and Their Recent Bets on Guardant Health OptionsSee More Headlines Receive GH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/03/2023Today5/29/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:GH CUSIPN/A CIK1576280 Webwww.guardanthealth.com Phone(855) 698-8887Fax888-974-4258Employees1,779Year FoundedN/APrice Target and Rating Average Stock Price Target$36.60 High Stock Price Target$50.00 Low Stock Price Target$27.00 Potential Upside/Downside+39.9%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-479,450,000.00 Net Margins-76.34% Pretax Margin-76.20% Return on Equity-246.47% Return on Assets-25.86% Debt Debt-to-Equity Ratio16.70 Current Ratio5.95 Quick Ratio5.66 Sales & Book Value Annual Sales$563.95 million Price / Sales5.68 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book46.71Miscellaneous Outstanding Shares122,370,000Free Float115,639,000Market Cap$3.20 billion OptionableNot Optionable Beta0.92 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Helmy Eltoukhy Ph.D. (Age 44)Co-Founder, Co-CEO & Chairman Comp: $11.63kDr. AmirAli Talasaz Ph.D. (Age 44)Co-CEO & Director Comp: $11.18kMr. Michael Bell (Age 55)Chief Financial Officer Comp: $630.99kMr. John G. Saia (Age 51)Chief Legal Officer & Corporate Secretary Comp: $627.18kDr. Craig Eagle M.D. (Age 57)Chief Medical Officer Comp: $649.13kMr. Christopher Freeman (Age 50)Chief Commercial Officer Comp: $630.39kMs. Darya ChudovaChief Technology OfficerMr. Kumud Kalia (Age 58)Chief Information Officer Ms. Jennifer HigginsVice President of Public AffairsMs. Terilyn Juarez Monroe (Age 57)Chief People Officer More ExecutivesKey CompetitorsGenetronNASDAQ:GTHExact SciencesNASDAQ:EXASRadNetNASDAQ:RDNTFortreaNASDAQ:FTREVeracyteNASDAQ:VCYTView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckyBought 10,000 shares on 5/28/2024Ownership: 0.125%Beck Bode LLCBought 60,851 shares on 5/22/2024Ownership: 0.166%Adalta Capital Management LLCBought 9,565 shares on 5/17/2024Ownership: 0.058%Comerica BankSold 9,109 shares on 5/17/2024Ownership: 0.001%Walleye Trading LLCSold 9,600 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions GH Stock Analysis - Frequently Asked Questions Should I buy or sell Guardant Health stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GH shares. View GH analyst ratings or view top-rated stocks. What is Guardant Health's stock price target for 2024? 13 Wall Street analysts have issued 12 month price objectives for Guardant Health's stock. Their GH share price targets range from $27.00 to $50.00. On average, they expect the company's stock price to reach $36.60 in the next twelve months. This suggests a possible upside of 39.9% from the stock's current price. View analysts price targets for GH or view top-rated stocks among Wall Street analysts. How have GH shares performed in 2024? Guardant Health's stock was trading at $27.05 at the beginning of 2024. Since then, GH stock has decreased by 3.3% and is now trading at $26.16. View the best growth stocks for 2024 here. Are investors shorting Guardant Health? Guardant Health saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 10,760,000 shares, an increase of 5.9% from the April 30th total of 10,160,000 shares. Based on an average daily volume of 2,270,000 shares, the short-interest ratio is currently 4.7 days. View Guardant Health's Short Interest. When is Guardant Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our GH earnings forecast. How were Guardant Health's earnings last quarter? Guardant Health, Inc. (NASDAQ:GH) posted its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($1.25) by $0.58. The firm earned $137.15 million during the quarter, compared to analysts' expectations of $129.44 million. Guardant Health had a negative net margin of 76.34% and a negative trailing twelve-month return on equity of 246.47%. Guardant Health's revenue was up 25.7% compared to the same quarter last year. During the same period last year, the business posted ($2.25) EPS. What ETFs hold Guardant Health's stock? ETFs with the largest weight of Guardant Health (NASDAQ:GH) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Tema Oncology ETF (CANC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), BNY Mellon Innovators ETF (BKIV), ARK Genomic Revolution ETF (ARKG) and iShares U.S. Healthcare Providers ETF (IHF).Invesco Nasdaq Biotechnology ETF (IBBQ). What guidance has Guardant Health issued on next quarter's earnings? Guardant Health issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $675.0 million-$685.0 million, compared to the consensus revenue estimate of $664.0 million. What is Helmy Eltoukhy's approval rating as Guardant Health's CEO? 52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Guardant Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO). When did Guardant Health IPO? Guardant Health (GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers. Who are Guardant Health's major shareholders? Guardant Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.40%), Baillie Gifford & Co. (5.12%), Capital International Investors (3.12%), Price T Rowe Associates Inc. MD (1.26%), Jennison Associates LLC (0.40%) and Mitsubishi UFJ Trust & Banking Corp (0.33%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Meghan V Joyce, Stanley J Meresman and Stanley J Meresman. View institutional ownership trends. How do I buy shares of Guardant Health? Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GH) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guardant Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.